HSC Specification via Transient Runx1-CBFβ Inhibition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for inducing hematopoietic stem cell (HSC) specificity and increasing HSC numbers are limited in efficacy and specificity, posing challenges for clinical applications such as HSC transplantation.

Innovation Solution

The method involves contacting cells with specific inhibitors, such as Ro5-3335, SU-5402, sc-221405, and AI-10-49, for a period of 1 to 6 days to induce HSC specification, followed by removal of the inhibitor to maintain long-term HSC activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current methods are used to induce HSC specificity, then HSC transplantation can be performed, but the efficacy and specificity are limited

Engineering Contradiction:

ImproveHSC transplantation successVSAvoidHSC specificity

Core Design Contradiction:

ReliabilityVSManufacturing precision

Solution Approach 1:

The patent uses small molecule inhibitors to modulate the activity of Runx1-CBFβ transcription factor complex, changing the biochemical parameters of cell differentiation. By inhibiting this complex during specific time windows, the method induces HSC specificity from progenitor cells with high efficiency and precision, resolving the contradiction between transplantation reliability and HSC specificity

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces small molecule inhibitors as intermediary substances that mediate the differentiation process. These inhibitors temporarily block Runx1-CBFβ activity, allowing precise control over HSC specification timing and quality, thereby improving both transplantation success and HSC specificity without requiring perfect donor-recipient matching

Inventive Principle:

Principle #24Intermediary (Mediator)

2Manufacturing precision

If the inhibitor is applied continuously, then HSC specification is maintained, but long-term HSC activity cannot be sustained

Engineering Contradiction:

ImproveHSC specificationVSAvoidlong-term HSC activity

Core Design Contradiction:

Manufacturing precisionVSDuration of action of stationary object

Solution Approach 1:

The patent employs periodic or transient application of inhibitors rather than continuous treatment. The inhibitor is applied during specific differentiation windows (e.g., days 3-6 of culture) to induce HSC specification, then removed to allow long-term HSC activity and self-renewal. This temporal control resolves the contradiction between maintaining specification and sustaining long-term function

Inventive Principle:

Principle #19Periodic action

Solution Approach 2:

The patent applies the inhibitor in advance during the differentiation phase to establish HSC specification before transplantation. Once the cells have acquired HSC properties through preliminary inhibitor treatment, the inhibitor is removed and the cells are transplanted, allowing them to maintain long-term activity without continuous drug exposure

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentEP3672590B1Methods for inducing hematopoietic stem cell specificity

Publication Date: 2025.02.12 CHILDRENS MEDICAL CENT CORP

Figure 1A~1C
Figure 1D
Figure 1D

AI summary

Described herein are methods for inducing HSC specification in a cell. Aspects of the invention relate to contacting a cell with a Runx1-CBFβ inhibitor for a specified period of time, and then removing the inhibitor from the cell. In some embodiments of any of the aspects, HSC specificity is maintained long-term.